Macular Degeneration
Conditions
Brief summary
This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.
Interventions
BIOLOGICALranibizumab
Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Sponsors
Bayer
Regeneron Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed Informed Consent. 2. Men and women ≥ 50 years of age. 3. Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye. 4. Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) of: letter score of 73 to 25 (20/40 to 20/320) in the study eye at 4 meters. 5. Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures. 6. Able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member. See Appendix J.4) understand and willing to sign the informed consent form. Key
Exclusion criteria
1. Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD except dietary supplements or vitamins. 2. Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye, except dietary supplements or vitamins. 3. Any prior treatment with anti-VEGF agents in the study eye. 4. Total lesion size \> 12 disc areas (30.5 mm\^2, including blood, scars and neovascularization) as assessed by FA in the study eye. 5. Subretinal hemorrhage that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. (If the blood is under the fovea, then the fovea must be surrounded 270 degrees by visible CNV.) 6. Scar or fibrosis, making up \> 50% of total lesion in the study eye. 7. Scar, fibrosis, or atrophy involving the center of the fovea. 8. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye. 9. History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye. 10. Presence of other causes of CNV in the study eye. 11. History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina,other than AMD, in either eye. 12. Prior vitrectomy in the study eye. 13. History of retinal detachment or treatment or surgery for retinal detachment in the study eye. 14. Any history of macular hole of stage 2 and above in the study eye. 15. Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as its unlikely to interfere with the injection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) | Baseline and at week 52 | Defined maintenance of vision as patients who lost fewer than 15 letters in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score compared to baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF | Baseline and at week 52 | Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning. |
| Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF. | Baseline and at week 52 | Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning. |
| Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF | Baseline and at Week 52 | The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight. |
| Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF) | Baseline and at week 52 | CNV area values measured in square millimeters (mm\^2); lower values represent better outcomes. |
Countries
Canada, United States
Participant flow
Recruitment details
The study was conducted at 164 sites in the United States and Canada. Recruitment period: 02 Aug 2007 to 15 Sep 2009.
Pre-assignment details
2063 patients were screened, 1217 randomized, and 1215 included in the Safety Analysis Set (SAF). The Full Analysis Set (FAS) included 1210 patients with at least 1 post-baseline assessment. The Per Protocol Set (PPS) included 1089 patients who received ≥ 9 doses of study drug and attended ≥ 9 scheduled visits during the first year.
Participants by arm
| Arm | Count |
|---|---|
| Ranibizumab 0.5mg Q4 Patients received a 0.5mg dose of ranibizumab via IVT injection every 4 weeks for the first year. | 304 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 Patients received a 2.0mg dose of Intravitreal Aflibercept Injection (IAI, EYLEA, VEGF Trap-Eye) every 4 weeks for the first year. | 304 |
| IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 Patients received a 0.5mg dose of Intravitreal Aflibercept Injection (IAI, EYLEA, VEGF Trap-Eye) every 4 weeks for the first year. | 304 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 Patients received a 2.0mg dose of Intravitreal Aflibercept Injection (IAI, EYLEA, VEGF Trap-Eye) every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. | 303 |
| Total | 1,215 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 4 | 3 | 5 | 4 |
| Overall Study | Death | 3 | 1 | 2 | 7 |
| Overall Study | Lack of Efficacy | 0 | 0 | 2 | 2 |
| Overall Study | Lost to Follow-up | 1 | 2 | 4 | 4 |
| Overall Study | OTHER | 1 | 0 | 4 | 1 |
| Overall Study | Protocol Violation | 3 | 0 | 3 | 1 |
| Overall Study | Withdrawal by Subject | 10 | 5 | 7 | 8 |
Baseline characteristics
| Characteristic | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | Total | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Ranibizumab 0.5mg Q4 |
|---|---|---|---|---|---|
| Age Continuous | 77.7 years STANDARD_DEVIATION 7.93 | 78.0 years STANDARD_DEVIATION 8 | 77.9 years STANDARD_DEVIATION 8.39 | 78.3 years STANDARD_DEVIATION 8.1 | 78.2 years STANDARD_DEVIATION 7.59 |
| Baseline Area of Choroidal Neovascularization (CNV) | 6.59 mm^2 STANDARD_DEVIATION 5.052 | 6.54 mm^2 STANDARD_DEVIATION 4.968 | 6.56 mm^2 STANDARD_DEVIATION 5.129 | 6.49 mm^2 STANDARD_DEVIATION 4.437 | 6.52 mm^2 STANDARD_DEVIATION 5.245 |
| Baseline Best Corrected Visual Acuity (BCVA) | 55.2 letters read STANDARD_DEVIATION 13.15 | 55.1 letters read STANDARD_DEVIATION 13.14 | 55.7 letters read STANDARD_DEVIATION 12.84 | 55.5 letters read STANDARD_DEVIATION 13.12 | 54.0 letters read STANDARD_DEVIATION 13.43 |
| Baseline Lesion Type Minimally Classic | 105 patients 0 | 415 patients | 112 patients 0 | 97 patients 0 | 101 patients 0 |
| Baseline Lesion Type Missing | 2 patients 0 | 12 patients | 2 patients 0 | 2 patients 0 | 6 patients 0 |
| Baseline Lesion Type Occult | 110 patients 0 | 466 patients | 118 patients 0 | 123 patients 0 | 115 patients 0 |
| Baseline Lesion Type Predominantly Classic | 87 patients 0 | 322 patients | 71 patients 0 | 82 patients 0 | 82 patients 0 |
| Baseline National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) total score | 70.4 scores on a scale STANDARD_DEVIATION 16.6 | 70.7 scores on a scale STANDARD_DEVIATION 17.11 | 69.5 scores on a scale STANDARD_DEVIATION 16.82 | 71.1 scores on a scale STANDARD_DEVIATION 17.72 | 71.7 scores on a scale STANDARD_DEVIATION 17.29 |
| Baseline Total Lesion Size | 6.98 mm^2 STANDARD_DEVIATION 5.388 | 6.95 mm^2 STANDARD_DEVIATION 5.202 | 6.88 mm^2 STANDARD_DEVIATION 5.214 | 6.96 mm^2 STANDARD_DEVIATION 4.711 | 6.99 mm^2 STANDARD_DEVIATION 5.491 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 11 Participants 0 | 41 Participants | 12 Participants 0 | 11 Participants 0 | 7 Participants 0 |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 293 Participants | 1174 Participants | 291 Participants | 293 Participants | 297 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants 0 | 5 Participants | 1 Participants 0 | 2 Participants 0 | 2 Participants 0 |
| Race (NIH/OMB) Asian | 3 Participants 0 | 12 Participants | 4 Participants 0 | 5 Participants 0 | 0 Participants 0 |
| Race (NIH/OMB) Black or African American | 1 Participants 0 | 3 Participants | 1 Participants 0 | 0 Participants 0 | 1 Participants 0 |
| Race (NIH/OMB) More than one race | 0 Participants 0 | 1 Participants | 1 Participants 0 | 0 Participants 0 | 0 Participants 0 |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants 0 | 2 Participants | 1 Participants 0 | 0 Participants 0 | 1 Participants 0 |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants 0 | 18 Participants | 6 Participants 0 | 3 Participants 0 | 4 Participants 0 |
| Race (NIH/OMB) White | 295 Participants 0 | 1174 Participants | 289 Participants 0 | 294 Participants 0 | 296 Participants 0 |
| Sex: Female, Male Female | 194 Participants | 714 Participants | 179 Participants | 169 Participants | 172 Participants |
| Sex: Female, Male Male | 110 Participants | 501 Participants | 124 Participants | 135 Participants | 132 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 261 / 304 | 254 / 304 | 262 / 304 | 258 / 303 |
| serious Total, serious adverse events | 94 / 304 | 70 / 304 | 88 / 304 | 90 / 303 |
Outcome results
Primary
Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)
Defined maintenance of vision as patients who lost fewer than 15 letters in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score compared to baseline.
Time frame: Baseline and at week 52
Population: PPS population used for analysis.
| Arm | Measure | Value (NUMBER) | Dispersion |
|---|---|---|---|
| Ranibizumab 0.5mg Q4 | Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) | 94.4 percentage of patients | 0 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) | 95.1 percentage of patients | 0 |
| IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) | 95.9 percentage of patients | 0 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) | 95.1 percentage of patients | 0 |
| Total | Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) | 95.1 percentage of patients | 0 |
Comparison: The statistical approach included a conditional sequence of calculations of the 95.1% CI using normal approximation of the difference between the proportion of patients with maintained vision at Week 52 for the group treated with 0.5 mg ranibizumab and the proportion of patients with maintained vision for each of the groups treated with IAI.95.1% CI: [-4.4, 3.1]
Comparison: The statistical approach included a conditional sequence of calculations of the 95.1% CI using normal approximation of the difference between the proportion of patients with maintained vision at Week 52 for the group treated with 0.5 mg ranibizumab and the proportion of patients with maintained vision for each of the groups treated with IAI (EYLEA, VEGF Trap-Eye).95.1% CI: [-5.1, 2.1]
Comparison: The statistical approach included a conditional sequence of calculations of the 95.1% CI using normal approximation of the difference between the proportion of patients with maintained vision at Week 52 for the group treated with 0.5 mg ranibizumab and the proportion of patients with maintained vision for each of the groups treated with IAI (EYLEA, VEGF Trap-Eye).95.1% CI: [-4.5, 3.1]
Secondary
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF
Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning.
Time frame: Baseline and at week 52
Population: FAS population used for analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ranibizumab 0.5mg Q4 | Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF | 8.1 letters read | Standard Deviation 15.25 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF | 10.9 letters read | Standard Deviation 13.77 |
| IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF | 6.9 letters read | Standard Deviation 13.41 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF | 7.9 letters read | Standard Deviation 15 |
| Total | Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF | 8.5 letters read | Standard Deviation 14.44 |
Comparison: The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline measure as covariate. The null hypothesis is that both mean changes are equal.p-value: 0.005495.1% CI: [0.92, 5.37]ANCOVA
Comparison: The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline measure as covariate. The null hypothesis is that both mean changes are equal.p-value: 0.479395.1% CI: [-3.03, 1.43]ANCOVA
Comparison: The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline measure as covariate. The null hypothesis is that both mean changes are equal.p-value: 0.817995.1% CI: [-1.97, 2.49]ANCOVA
Secondary
Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF)
CNV area values measured in square millimeters (mm\^2); lower values represent better outcomes.
Time frame: Baseline and at week 52
Population: FAS population used for analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ranibizumab 0.5mg Q4 | Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF) | -4.2 mm^2 | Standard Deviation 5.59 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF) | -4.6 mm^2 | Standard Deviation 5.47 |
| IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF) | -3.5 mm^2 | Standard Deviation 5.27 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF) | -3.4 mm^2 | Standard Deviation 6.02 |
| Total | Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF) | -3.9 mm^2 | Standard Deviation 5.61 |
Comparison: The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline measure as covariate. The null hypothesis is that both mean changes are equal.p-value: 0.357595.1% CI: [-1.04, 0.38]ANCOVA
Comparison: The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline measure as covariate. The null hypothesis is that both mean changes are equal.p-value: 0.050795.1% CI: [-0.01, 1.42]ANCOVA
Comparison: The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline measure as covariate. The null hypothesis is that both mean changes are equal.p-value: 0.017395.1% CI: [0.15, 1.58]ANCOVA
Secondary
Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.
Time frame: Baseline and at Week 52
Population: FAS population used for analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Ranibizumab 0.5mg Q4 | Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF | 4.9 scores on a scale | Standard Deviation 14.01 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF | 6.7 scores on a scale | Standard Deviation 13.5 |
| IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF | 4.5 scores on a scale | Standard Deviation 11.87 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF | 5.1 scores on a scale | Standard Deviation 14.74 |
| Total | Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF | 5.3 scores on a scale | Standard Deviation 13.59 |
Comparison: The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline measure as covariate. The null hypothesis is that both mean changes are equal.p-value: 0.20995.1% CI: [-0.73, 3.28]ANCOVA
Comparison: The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline measure as covariate. The null hypothesis is that both mean changes are equal.p-value: 0.512895.1% CI: [-2.69, 1.35]ANCOVA
Comparison: The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline measure as covariate. The null hypothesis is that both mean changes are equal.p-value: 0.557995.1% CI: [-2.61, 1.42]ANCOVA
Secondary
Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF.
Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning.
Time frame: Baseline and at week 52
Population: FAS population used for analysis.
| Arm | Measure | Value (NUMBER) | Dispersion |
|---|---|---|---|
| Ranibizumab 0.5mg Q4 | Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF. | 30.9 percentage of patients | 0 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF. | 37.5 percentage of patients | 0 |
| IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF. | 24.9 percentage of patients | 0 |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF. | 30.6 percentage of patients | 0 |
| Total | Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF. | 31.1 percentage of patients | 0 |
Comparison: The null hypothesis is that both percentages are equal.p-value: 0.104295.1% CI: [-1, 14.1]Chi-squared
Comparison: The null hypothesis is that both percentages are equal.p-value: 0.103795.1% CI: [-13.2, 1.2]Chi-squared
Comparison: The pairwise The null hypothesis is that both percentages are equal.p-value: 0.9395.1% CI: [-7.7, 7]Chi-squared